IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4437
Positioning
Market Dominance
Manufacturing
Chemicals
$142M
Eric A. McAfee
Aemetis, Inc. focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners. The company also produces and sells ethanol; and wet distillers grains to dairies and feedlots as animal feed.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$AMTX AEMETIS, INC | 31 | 22 | 48 | 20 | - | - | 13.5% | -37.2% | -3.4% | -19.0% | -41.0% | -11.1% | 0.0% | - | $142M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
AEMETIS, INC (AMTX) receives a "Avoid" rating with a composite score of 31.3/100. It ranks #4437 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
Eric A. McAfee
Chief Executive Officer
Labor Force
160
22
35
33
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for AMTX
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for AMTX.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROIC -1.9% vs WACC 4.4% (spread -6.3%)
GM -3% vs sector 43%, OM -19% vs sector 1%
Capital turnover 0.17x
Rev growth -11%, 10yr history
Interest coverage -0.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags AEMETIS, INC with an Avoid rating, assigning a composite score of 31.3/100 and 1 out of 5 stars. Ranked #4437 of 7,333 stocks, AMTX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
AEMETIS, INC registers a weak quality score of just 22/100, indicating significant profitability challenges. The company reports a return on equity of 13.5% (sector avg: -2.5%), gross margins of -3.4% (sector avg: 42.5%), net margins of -41.0% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 48/100, AMTX appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
AEMETIS, INC's investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -11.1% vs. a sector average of 5.9% and a return on assets of -37.2% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
AEMETIS, INC is experiencing notably weak momentum with a score of just 20/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -11.1% year-over-year, while a beta of 1.40 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
AMTX's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.40. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
AEMETIS, INC's short interest score of 38/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.40), micro-cap liquidity risk. At $142M (micro-cap), AMTX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
AEMETIS, INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4437 of 7,333 overall (39th percentile). Key comparisons include ROE of 13.5% exceeding the -2.5% sector median and operating margins of -19.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While AMTX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (20) would have the largest impact on the composite score.
ROE 644% BELOW SECTOR MEDIAN
Gross Margin 108% BELOW SECTOR MEDIAN
Op. Margin 1569% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate AEMETIS, INC (AMTX) as Avoid with a composite score of 31.3/100 at a current price of $1.42. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in value (48th percentile) and investment (35th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (20th percentile) and quality (22th percentile) tempers our overall conviction. We assign a No Moat rating (13/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
AEMETIS, INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 31.3/100 places it at rank #4437 in our full 7,333-stock universe. At $142M in market capitalization, AEMETIS, INC is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -11% combined with momentum at the 20th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of -3% (-45.9pp vs sector) narrow to operating margins of -19% (-20.2pp vs sector) and net margins of -41.0%, yielding a gross-to-net conversion rate of N/A%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $1.42, AEMETIS, INC is trading near fair value based on current fundamentals. Our value factor score of 48/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/S of 0.4x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 31.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -11% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -41.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (20th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to AEMETIS, INC. Key risk factors include elevated market sensitivity (beta of 1.40), current negative profitability (net margin -41.0%), below-average price stability (33th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.40); current negative profitability (net margin -41.0%); below-average price stability (33th percentile); weak quality scores (22th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 33th percentile and quality factor at the 22th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate AEMETIS, INC's capital allocation as Poor. Key concerns include negative profitability, weak asset returns (ROA -37.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — AEMETIS, INC significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, AEMETIS, INC receives a Avoid rating with a composite score of 31.3/100 (rank #4437 of 7,333). Our quantitative framework assigns a No Moat (13/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on AEMETIS, INC at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign AEMETIS, INC a meaningful economic moat, scoring 13/100 on our composite assessment. The ROIC-WACC spread of -6.3% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, economic value creation, reached only 5.1/20.
The strongest moat sources are economic value creation (5.1/20) and growth durability (4.2/20). ROIC -1.9% vs WACC 4.4% (spread -6.3%). Rev growth -11%, 10yr history. These pillars form the core of AEMETIS, INC's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and margin superiority (0.7/20). Capital turnover 0.17x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect AEMETIS, INC's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-11%) that pressure the earnings outlook. The margin cascade from -3% gross to -19% operating to -41.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 22th percentile.
The margin profile shows gross margins of -3%, operating margins of -19%, net margins of -41.0%. Return metrics include ROE of 13.5% and ROA of -37.2%. Relative to the Manufacturing sector, gross margins are 45.9 percentage points below the sector median of 43%, and ROE of 13.5% compares to a sector median of -2.5%.
The balance sheet reflects revenue growth of -11%. Overall balance sheet health is adequate for the current business environment.
Below-average quality (22th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.

Aemetis (AMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CUPERTINO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX), a diversified renewable natural gas and biofuels company, announced that its Universal Biofuels subsidiary in India secured allocations of approximately $24 million for the supply of more than 27 million liters of biodiesel to India’s three government-owned Oil Marketing Companies (OMCs) for the period ending March 2026. Additional OMC fuel supply orders are expected throughout the year to support the India govern
Aemetis, Inc. ( NASDAQ:AMTX ) shareholders are no doubt pleased to see that the share price has bounced 39% in the last...

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. Cutera posted adjusted loss of $1.36 per share, compared to market estimates for a loss of 94 cents per share. The company’s quarterly sales came in at $49.540 million, versus expectations of $47.500 million, according to data from Benzinga Pro. Cutera shares dipped 26.5% to $1.6899 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Murano Global Investments PLC (NASDAQ: MRNO) shares jumped 147.5% to $23.94 after falling 46% on Thursday. Nova LifeStyle, Inc. (NASDAQ: NVFY) surged 120% to $4.0301 after gaining around 22% on Thursday. BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 50.4% to $0.2256 after the company reported better-than-expected fourth-quarter earnings results. IMAC Holdings, Inc. (NASDAQ: BACK) gained 41.1% to $1.8204. Summit Midstream Partners, LP (NYSE: SMLP) surged 36.1% to $26.45 after the company announced the sale of its Utica position for $625 million. Outlook Therapeutics, Inc. (NASDAQ: OTLK) gained 32.1% to $9.30 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD. GT Biopharma, Inc. (NASDAQ: GTBP) gained 27.6% to $4.86. Aemetis, Inc. (NASDAQ: AMTX) rose 21% to $6.21. Aemetis recently announced approval by the U.S. Citizenship and Immigration Services for a $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel, production plant, the dairy renewable natural gas project, the carbon sequestration project and energy efficiency upgrades to the Keyes ethanol plant. Foresight Autonomous Holdings Ltd. (NASDAQ: ...
With the business potentially at an important milestone, we thought we'd take a closer look at Aemetis, Inc.'s...
Above 50MA
37.18%
Net New Highs
+51081